ConferenceMay 27, 2026153 days ago
Phase 3 HERIZON-GEA-01 Ziihera results published in NEJM
Jazz presented data on Ziihera (zanidatamab-hrii) for 1L HER2+ locally advanced or metastatic GEA at a medical meeting on May 27, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsData presented at a medical meeting
- Company
- Jazz Pharmaceuticals plc JAZZ
- Drug
- Ziihera (zanidatamab-hrii)
- For
- 1L HER2+ locally advanced or metastatic GEA
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- May 27, 2026
- Source note
- NEJM published the pivotal Phase 3 HERIZON-GEA-01 results for zanidatamab plus chemotherapy, with and without tislelizumab, in first-line HER2+ gastroesophageal adenocarcinoma, building on the late-breaking oral presentation at ASCO GI 2026.
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: investor.jazzpharma.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- JAZZ headlines on this site
Jazz Pharmaceuticals plc
1 upcoming · 7 past catalysts
More from JAZZ
Jazz expects to report results from its Phase 3 study of Modeyso (dordaviprone) for Recurrent H3 K27M-mutant diffuse glioma in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Modeyso ACTION Phase 3 interim OS analysis · Clinical trial results (readout / topline data)
- Drug
- Modeyso (dordaviprone)
- For
- Recurrent H3 K27M-mutant diffuse glioma
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Q2 2026 results: company anticipates the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, supporting potential full approval.
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- JAZZ headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page